Review
Immunology
Michela Luciano, Peter W. Krenn, Jutta Horejs-Hoeck
Summary: Acute myeloid leukemia (AML) is a heterogeneous blood cancer with complex disease characteristics and cytokine networks, making treatment challenging. The development of new targeted therapies and understanding the functions of cytokines are important for improving treatment options.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pediatrics
Chompoonut Limratchapong, Praewa Sophark, Prayong Vachvanichsanong, Edward B. McNeil, Thirachit Chotsampancharoen
Summary: This study examined the prevalence and factors associated with acute kidney injury (AKI) in children with acute myeloid leukemia (AML) during chemotherapy treatment. The results showed that 50% of the children developed AKI, and age at diagnosis ≥ 10 years, glomerular filtration rate < 90 mL/min/1.73 m² at AML diagnosis, and septic shock were strongly associated with AKI.
PEDIATRIC NEPHROLOGY
(2022)
Article
Oncology
Qian Peng, Renhua Huang, Huiping Wang, Hao Xiao, Yiping Wang, Zhimin Zhai, Zhitao Wang
Summary: This study investigated the immune characteristics of mucosal-associated invariant T cells (MAITs) in patients with acute myeloid leukemia (AML) and found that these cells may play a crucial role in AML pathogenesis and treatment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Chemistry, Medicinal
Serena Tseng, Mu-En Lee, Pei-Chin Lin
Summary: Acute myeloid leukemia (AML) is the second most common hematologic malignancy in children, and its rarity makes the new genetic abnormality classifications and risk group classifications significant for the management and prognosis prediction in childhood AML. This review focuses on the well-known genetic subtypes in childhood AML and discusses the current treatment algorithms, novel treatment modalities, and indications of hematopoietic stem cell transplantation (HSCT).
Review
Biochemistry & Molecular Biology
Omid Karimdadi Sariani, Sara Eghbalpour, Elahe Kazemi, Kimia Rafiei Buzhani, Farhad Zaker
Summary: Acute myeloid leukemia (AML) is a deadly disease that is highly common in adults. Cytokines play a crucial role in the development of AML, and imbalanced release may impact disease progression. Studying cytokines is essential for the treatment and survival of AML patients.
Article
Hematology
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, Martha L. Arellano, Kendra L. Sweet, Ashkan Emadi, Farhad Ravandi, Harry P. Erba, Michael Byrne, Laura Michaelis, Max S. Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin A. Huls, Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Recher, Patrick J. Stiff, Kristen M. Pettit, Bob Lowenberg, Sarah E. Church, Erica Anderson, Jayakumar Vadakekolathu, Marianne Santaguida, Michael P. Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B. Walter, Jan K. Davidson-Moncada, Sergio Rutella, John F. DiPersio
Summary: This study presents the results of a multicenter, open-label, phase 1/2 study of flotetuzumab in 88 adults with relapsed/refractory AML, showing clinical benefits in PIF/ER patients and encouraging evidence of activity. Flotetuzumab represents an innovative experimental approach associated with acceptable safety.
Article
Hematology
Qing Zhang, Haotian Yan, Xiyang Ren, Linlin Liu, Juan Wang, Lulu Zhang, Yi Dong, Hui Qin, Qianshan Tao, Zhimin Zhai
Summary: Platelet counts are found to be associated with prognosis in patients with acute myeloid leukemia (AML). High platelet counts are correlated with high-risk molecular cytogenetic stratification, low complete remission rate, poor leukemia-free survival, high proportion of leukemia stem cells, and increased levels of immunomodulatory cytokines and immune cell subsets in AML.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Honghong Zhang, Yang Wan, Hongsheng Wang, Jiaoyang Cai, Jie Yu, Shaoyan Hu, Yongjun Fang, Ju Gao, Hua Jiang, Minghua Yang, Changda Liang, Runming Jin, Xin Tian, Xiuli Ju, Qun Hu, Hui Jiang, Zhifan Li, Ningling Wang, Lirong Sun, Alex W. K. Leung, Xuedong Wu, Xiaowen Qian, Maoxiang Qian, Chi-kong Li, Jun Yang, Jingyan Tang, Xiaofan Zhu, Shuhong Shen, Li Zhang, Ching-Hon Pui, Xiaowen Zhai
Summary: The study aims to identify prognostic factors for improving the outcome of patients with TCF3::PBX1 ALL. The presence of positive MRD and testicular leukemia are indicators for new molecular therapeutics or immunotherapy in these patients.
Editorial Material
Cell & Tissue Engineering
Malini Gupta, Britta Will
Summary: Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this study, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as a targeted opportunity for mitigating malignant cell growth in AML.
Article
Multidisciplinary Sciences
Can Yue, Siting Xie, Jiaying Zhong, Haijun Zhao, Zhijuan Lin, Li Zhang, Bing Xu, Yiming Luo
Summary: The study found that SCAMP2/4/5 may serve as potential prognostic markers for AML, and SCAMP2 and SCAMP5 individually or in combination may be utilized as diagnostic markers for AML.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Feng-Ting Dao, Jun Wang, Lu Yang, Ya-Zhen Qin
Summary: The study identified 64 immune-related differentially expressed genes (DEGs) associated with mutations in AML and developed an immune prognostic model (IPM) composed of PYCARD and PEAR1 genes, which independently predicted lower 2-year overall survival rates in AML patients. The IPM was validated in different databases and found to be associated with specific immune cell proportions and expression of checkpoint molecules in the AML cohort. The IPM derived from poor prognosis mutations in AML provides new biomarkers for patient stratification and personalized immunotherapy.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Jeremy M. Schraw, Helen D. Bailey, Audrey Bonaventure, Ana M. Mora, Eve Roman, Beth A. Mueller, Jacqueline Clavel, Eleni T. Petridou, Maria Karalexi, Evangelia Ntzani, Sameera Ezzat, Wafaa M. Rashed, Erin L. Marcotte, Logan G. Spector, Catherine Metayer, Alice Y. Kang, Corrado Magnani, Lucia Miligi, John D. Dockerty, Juan Manuel Mejia-Arangure, Juan Carlos Nunez-Enriquez, Claire Infante-Rivard, Elizabeth Milne, Michael E. Scheurer
Summary: Growing evidence suggests that breastfeeding may have a protective effect against childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This study analyzed data from multiple studies and found that longer breastfeeding duration is associated with decreased odds of ALL and AML.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Zhiheng Cheng, Yifeng Dai, Wenhui Huang, Qingfu Zhong, Pei Zhu, Wenjuan Zhang, Zhihua Wu, Qing Lin, Huoyan Zhu, Longzhen Cui, Tingting Qian, Cong Deng, Lin Fu, Yan Liu, Tiansheng Zeng
Summary: The study indicates that high expression of miR-20b is a poor prognostic indicator for AML, but allogeneic hematopoietic stem cell transplantation (allo-HSCT) may override its prognostic impact.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Mei-Si Lin, Hui-Yun Zhong, Rita Lok-Hay Yim, Qi-Yan Chen, Hong-Ling Du, Hao-Qi He, Ke Lin, Peng Zhao, Ru Gao, Fei Gao, Min-Yue Zhang
Summary: The TNFAIP2 gene is found to be overexpressed in AML patients and is associated with poor prognosis. The immunoregulation and inflammation response functions of TNFAIP2 play important roles in leukemogenesis.
Review
Oncology
Kristen J. Kurtz, Shannon E. Conneely, Madeleine O'Keefe, Katharina Wohlan, Rachel E. Rau
Summary: Acute myeloid leukemia (AML) is a genetically and phenotypically heterogeneous hematologic malignancy. Murine models of AML are indispensable research tools to better understand the mechanisms and test novel therapeutic approaches for this disease.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biophysics
Roland B. Walter, Robert Peter Gale
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Corentin Orvain, Jacob A. Wilson, Min Fang, Brenda M. Sandmaier, Eduardo Rodriguez-Arboli, Brent L. Wood, Megan Othus, Frederick R. Appelbaum, Roland B. Walter
Summary: Measurable residual disease (MRD) before hematopoietic cell transplantation (HCT) is an independent prognostic factor for acute myeloid leukemia (AML) patients. The combination of residual cytogenetic abnormalities and MRD testing by multiparameter flow cytometry (MFC) improves risk assessment before HCT and provides complementary prognostic information for post-HCT outcomes in patients with cytogenetically abnormal AML undergoing allogeneic HCT.
Article
Oncology
Thomas W. LeBlanc, Nigel H. Russell, Loriana Hernandez-Aldama, Charlotte Panter, Timothy J. Bell, Verna Welch, Diana Merino Vega, Louise O'Hara, Julia Stein, Melissa Barclay, Francois Peloquin, Andrew Brown, Jasmine Healy, Lucy Morgan, Adam Gater, Ryan Hohman, Karim Amer, Dawn Maze, Roland B. Walter
Summary: This study reveals the value of extending survival in treatment decision-making for older adults with acute myeloid leukemia and emphasizes the importance of addressing the differences and communication issues between patients and physicians in the decision-making process.
ONCOLOGY AND THERAPY
(2022)
Letter
Biophysics
Eduardo Rodriguez-Arboli, Corentin Orvain, Megan Othus, Roland B. Walter
BONE MARROW TRANSPLANTATION
(2022)
Letter
Oncology
Megan Othus, Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Mia Sydenham, Robert K. Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Nigel Russell, Kathleen F. Kerr, Roland B. Walter, Mike Dennis
LEUKEMIA & LYMPHOMA
(2023)
Article
Biophysics
Roland B. Walter, Brenda M. Sandmaier, Megan Othus, Corentin Orvain, Eduardo Rodriguez-Arboli, Masumi U. Oshima, Gary Schoch, Chris Davis, H. Joachim Deeg, Rainer Storb
Summary: Reduced intensity conditioning (RIC) and nonmyeloablative (NMA) conditioning regimens are viable options for allogeneic hematopoietic cell transplantation (HCT) in AML patients. However, the relative efficacies and toxicities of these regimens are not well-defined. This study compared outcomes between RIC and NMA HCT patients and found no significant differences in relapse risk, relapse-free survival, overall survival, and non-relapse mortality. These findings suggest that the choice between RIC and NMA conditioning may not significantly impact outcomes in AML patients undergoing allografting.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Gabrielle Paras, Megan Othus, Kelda Schonhoff, Carole Shaw, Mohamed Sorror, Anna B. Halpern, Jacob Appelbaum, Paul Hendrie, Roland B. Walter, Elihu H. Estey, Mary-Elizabeth M. Percival
Letter
Oncology
Sarit Assouline, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, Geoffrey L. Uy, Lisa Y. Law, Faisal Cheema, Kendra L. Sweet, Adam S. Asch, Jijun (Jane) Liu, Anna B. Moseley, Tracy Maher, Laura L. Kingsbury, Min Fang, Jerald Radich, Richard F. Little, Harry P. Erba
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Corentin Orvain, Eduardo Rodriguez-Arboli, Megan Othus, Brenda M. Sandmaier, H. Joachim Deeg, Frederick R. Appelbaum, Roland B. Walter
Summary: This study retrospectively analyzed 739 patients with de novo AML, 125 with antecedent hematologic disorder (AHD)/AML, and 115 with therapy-related AML who received allografts while in first or second remission. The results showed that relative to patients with de novo AML, relapse rates were similar for patients with AHD and therapy-related AML after multivariable adjustment, as were relapse-free survival and overall survival. Non-relapse mortality was higher for AHD AML. These findings suggest that the clinical history by itself has limited prognostic value for AML patients undergoing allografting.
Editorial Material
Oncology
Raffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Roland Bruno Walter, Adriano Venditti, Francesco Buccisano
Article
Oncology
Michelle Y. Y. Zhang, Megan Othus, Carole Shaw, Kelda G. G. Schonhoff, Anna B. B. Halpern, Jacob Appelbaum, Paul C. C. Hendrie, Roland B. B. Walter, Elihu H. H. Estey, Mary-Elizabeth M. Percival
Summary: Patients with acute myeloid leukemia (AML) who have previously received hypomethylating agents (HMA) have a poor prognosis. High intensity induction chemotherapy may improve outcomes in these patients.
LEUKEMIA & LYMPHOMA
(2023)
Letter
Oncology
Noam E. Kopmar, Ted Gooley, Niall Curley, Kathryn Russell, Carole Shaw, Kelda Schonhoff, John Lim, Anna B. Halpern, Roland B. Walter, Bart L. Scott, Jacob Appelbaum, Paul C. Hendrie, Elihu H. Estey, Mary-Elizabeth M. Percival
LEUKEMIA & LYMPHOMA
(2023)
Letter
Oncology
Lauren Shih, Megan Othus, Kelda Schonhoff, Carole Shaw, Jacob Appelbaum, Anna B. Halpern, Pamela S. Becker, Roland B. Walter, Elihu Estey, Mary-Elizabeth Percival
Correction
Hematology
Jesse M. Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B. Walter, Brent L. Wood, Christophe Roumier, Jan Philippe, Barbara Denys, Jeffrey L. Jorgensen, Marie C. Bene, Francis Lacombe, Adriana Plesa, Monica L. Guzman, Agnieszka Wierzbowska, Anna Czyz, Lok Lam Ngai, Adrian Schwarzer, Costa Bachas, Jacqueline Cloos, Marion Subklewe, Michaela Fuering-Buske, Francesco Buccisano
Article
Hematology
Jesse M. Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B. Walter, Brent L. Wood, Christophe Roumier, Jan Philippe, Barbara Denys, Jeffrey L. Jorgensen, Marie C. Bene, Francis Lacombe, Adriana Plesa, Monica L. Guzman, Agnieszka Wierzbowska, Anna Czyz, Lok Lam Ngai, Adrian Schwarzer, Costa Bachas, Jacqueline Cloos, Marion Subklewe, Michaela Fuering-Buske, Francesco Buccisano
Summary: Experts from the MRD Working Party of the European LeukemiaNet evaluated the key factors for accurate MFC-MRD measurement in acute myeloid leukemia (AML) and provided recommendations to ensure quality and reproducibility of results. The recommendations were tested by comparing two 8-color MRD panels in multiple laboratories, confirming their feasibility.